CAR-NK cell therapy in AML: Current treatment, challenges, and advantage
Mohammadmahdi Bahramloo, Sina Alinejad Shahabi, Hossein Kalarestaghi, Ali Rafat, Zeinab Mazloumi, Arian Samimifar, Khadijeh Dizaji Asl
Abstract
Over the last decade, discovery of novel therapeutic method has been attention by the researchers and has changed the therapeutic perspective of hematological malignancies. Although NK cell play a pivotal role in the elimination of abnormal and cancerous cells, there are evidence that NK cell are disarm in hematological malignancy. Chimeric antigen receptor NK (CAR-NK) cell therapy, which includes the engineering of NK cells to detect tumor-specific antigens and, as a result, clear of cancerous cells, has created various clinical advantage for several human malignancies treatment. In the current review, we summarized NK cell dysfunction and CAR-NK cell based immunotherapy to treat AML patient.